Strikingly, similar to anti-PD-1 and SGT-53 combination study, BLI-based measurement revealed a significant inhibition of tumor growth associated with the anti-PD-1 and scL-siGAL combination treatment (Figure S3B,C) with a significant survival benefit (Figure S3D). Here, PDCD1 is linked to neoplasm.